TP53 and hepatocellular carcinoma: Freimel et al. examined 120 tumour areas from 23 treatment-naïve HCC patients and showed that 87% of the cases exhibited intra-tumoural heterogeneity (ITH) in tissue morphology by immunohistochemistry (IHC) and had TP53 and CTNNB1 mutations [20].